

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant(s): John G. Babish, et al.  
Application No: 10/557,293  
Confirmation No.: 9021  
Art Unit: 1655  
Filed: December 20, 2006  
Title: ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS FOR  
REDUCING INFLAMMATION AND THE TREATMENT OR  
PREVENTION OF GASTRIC TOXICITY  
Docket No.: 068911-0126

---

**CERTIFICATE OF TRANSMISSION**

I hereby certify that this correspondence is being deposited with the U.S. Postal Service via First Class Mail in an envelope addressed to: Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or facsimile transmitted (571) 273-8300 or filed via EFS-Web to the USPTO, on the date indicated below.

Date: August 31, 2010

  
Jacqueline Andreu

---


**MAIL STOP ISSUE FEE**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**STATEMENT OF ENTITY STATUS CHANGE NOTIFICATION**  
**UNDER 37 CFR § 1.27(g)(2)**

The assignee of the above-referenced patent application now qualifies as a LARGE entity and the small entity status is no longer applicable. The Issue Fee Transmittal reflecting the changes in the entity status is concurrently filed with this notification. The Commissioner is hereby authorize to charge LARGE ENTITY fees for issue fee payment, any deficiency, or credit any overpayment, to deposit Account Number 50-1133. If you have any questions regarding this matter, please contact the undersigned.

Respectfully submitted,

McDERMOTT WILL & EMERY LLP



Atabak R. Royace, Ph.D.

Registration No. 59,037

28 State Street

Boston, MA 02109 – 1775

Telephone: 617-535-4108

Facsimile: 617-535-3800

Date: August 31, 2010